Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 29;8(2):153.
doi: 10.3390/vaccines8020153.

Progress and Prospects on Vaccine Development against SARS-CoV-2

Jinyong Zhang  1 , Hao Zeng  1 , Jiang Gu  1 , Haibo Li  1 , Lixin Zheng  2 , Quanming Zou  1
Affiliations
Review

Progress and Prospects on Vaccine Development against SARS-CoV-2

Jinyong Zhang et al. Vaccines (Basel). .

Abstract

In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.

Keywords: SARS-CoV-2; adjuvant; animal model; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic of the overall structure of SARS-CoV-2.
See this image and copyright information in PMC

References

    1. Hui D.S., Azhar E., Madani T.A., Ntoumi F., Kock R., Dar O., Ippolito G., McHugh T.D., Memish Z.A., Drosten C., et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis. 2020;91:264–266. doi: 10.1016/j.ijid.2020.01.009. - DOI - PMC - PubMed
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
    1. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—An update on the status. Mil. Med. Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0. - DOI - PMC - PubMed
    1. Phan T. Novel coronavirus: From discovery to clinical diagnostics. Infect. Genet. Evolut. J. Mol. Epidemiol. Evolut. Genet. Infect. Dis. 2020;79:104211. doi: 10.1016/j.meegid.2020.104211. - DOI - PMC - PubMed
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 doi: 10.1016/j.cell.2020.02.052. - DOI - PMC - PubMed

LinkOut - more resources